Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab.
Passeron T, Perrot JL, Jullien D, Goujon C, Ruer M, Boyé T, Villani AP, Quiles Tsimaratos N. Passeron T, et al. Among authors: villani ap. JAMA Dermatol. 2024 Feb 1;160(2):199-203. doi: 10.1001/jamadermatol.2023.5051. JAMA Dermatol. 2024. PMID: 38054800 Free PMC article.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: villani ap. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: Week 104 results from the SUNSHINE and SUNRISE extension trial.
Kimball AB, Bechara FG, Badat A, Giamarellos-Bourboulis EJ, Gottlieb AB, Jemec GBE, Reguiai Z, Villani AP, Alarcon I, Bansal A, Gasperoni F, Martin R, Paguet B, Uhlmann L, Zouater H, Ravichandran S, Alavi A. Kimball AB, et al. Among authors: villani ap. Br J Dermatol. 2024 Nov 29:ljae469. doi: 10.1093/bjd/ljae469. Online ahead of print. Br J Dermatol. 2024. PMID: 39611771
Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm.
Poizeau F, Leducq S, Fardet L, Beylot-Barry M, Chaby G, Chastagner M, Corgibet F, Gouillon L, Jouan N, Jullien D, Acher A, Amatore F, Amici JM, Aubert H, Aubin F, Beneton N, Bouilly D, Bursztejn AC, Buzenet C, Chamaillard-Pujol M, Charles J, Cottencin-Charriere AC, Duval Modeste B, Fauconneau A, Fougerousse AC, Girard C, Goujon C, Khemis A, Le Ru Y, Lepelley-Dupont C, Mahé E, Marcellin X, Nicolas C, Pallure V, Parier J, Quiles N, Stoebner PE, Tauber M, Vermersch A, Viguier M, Villani AP, Chosidow O, Guillot B; Psoriasis Research Group (GRPso) and the Centre of Evidence of the French Society of Dermatology. Poizeau F, et al. Among authors: villani ap. Ann Dermatol Venereol. 2024 Sep;151(3):103287. doi: 10.1016/j.annder.2024.103287. Epub 2024 Jul 15. Ann Dermatol Venereol. 2024. PMID: 39013256 Free article.
Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis.
Morot J, Del Duca E, Chastagner M, Fernandes M, Estrada Y, Lefevre MA, Kanitakis J, Harou O, Jullien D, Nicolas JF, Krueger JG, Vocanson M, Guttman-Yassky E, Villani AP. Morot J, et al. Among authors: villani ap. JAMA Dermatol. 2023 Aug 1;159(8):820-829. doi: 10.1001/jamadermatol.2023.1651. JAMA Dermatol. 2023. PMID: 37342057 Free PMC article.
71 results